Nine Chapters Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Nine Chapters Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-43,500	Closed	-$183K	–	262
2017 Q1	$183K	Buy	43,500 +41,780	+2,429%	+$193K	0.25%	165
2016 Q4	$7K	Sell	1,720 -770	-31%	-$3.19K	0.01%	172
2016 Q3	$9K	Buy	+2,490	New	+$9.07K	0.06%	74
2015 Q2	–	Sell	-6,220	Closed	-$113K	–	1319
2015 Q1	$113K	Buy	+6,220	New	+$140K	0.01%	884
2014 Q4	–	Sell	-3,190	Closed	-$77K	–	1370
2014 Q3	$77K	Sell	3,190 -800	-20%	-$20.8K	0.01%	942
2014 Q2	$112K	Buy	+3,990	New	+$120K	0.01%	874
2013 Q3	–	Sell	-1,730	Closed	-$18K	–	1022
2013 Q2	$18K	Buy	+1,730	New	+$20.3K	﹤0.01%	612

Other funds holding CTIC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return

Nine Chapters Capital Management's CTIC Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2017, closing a stake of 43,500 shares — an estimated $183K sold.

Nine Chapters Capital Management first reported a position in CTIC in Q2 2013 and held it in 7 quarters. The position peaked at $183K in Q1 2017. 40 funds tracked by Wall St. Rank hold CTIC as of Q2 2017.

Nine Chapters Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2017 after selling out during the quarter.
Nine Chapters Capital Management sold 43,500 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2017, an estimated $183K.
Nine Chapters Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 7 quarters.
Nine Chapters Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $183K in Q1 2017.
40 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.